Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

WideCells Group clinches deal to launch stem cell insurance product in Asia

The healthcare services group said the agreement had been signed with Cryoviva, a cord blood storage facility with operations in Thailand, Singapore and India
Medical Microscope
CellPlan allows users to store their stem cells for treatment in the future

WideCells Group PLC (LON:WDC) has signed a deal to bring its stem cell insurance product, CellPlan, to the Asian market.

The London main market-listed healthcare services group said the agreement had been signed with Cryoviva, a cord blood storage facility with operations in Thailand, Singapore and India.

READ: WideCells granted Innovate UK Knowledge Transfer Partnership for stem cell technology

CellPlan allows users to store their stem cells for treatment in the future, protecting them from unforeseen healthcare costs, with an average cost of £170 per annum.

The company added that Cryoviva to date had almost 250,000 inspected samples stored, with forecasts to store around 25,000 new samples per year going forward.

The product will be launched to Cryoviva customers on a phased basis, commencing in the second half of 2018, and would provide staged revenue increases, WideCells said.

WATCH: WideCells secures deal with international stem cell storage giant

The agreement will be another step in geographical expansion for the group, following recent contracts in both Europe and South America.

João Andrade, WideCells chief executive, commented: "With over 250,000 clients, established operations in three countries and around 25,000 new samples being stored every year, this deal with Cryoviva is set to transform the revenue profile of our company.  Our innovative insurance product has the potential to revolutionise the stem cell market by making treatment much more affordable.

He added: “This strategic agreement with Cryoviva will enable us to launch CellPlan in one of the fastest growing stem cell markets where there is clear demand for stem cell services.  By implementing a staged roll-out model, we are able to ensure the stable growth of our operations in each country and provide a solid base for continued growth."

View full WDC profile View Profile

WideCells Group Timeline

Related Articles

June 06 2018
Ventripoint received key FDA approval to sell the device with the four-chamber heart analysis last month
Proton Therapy sign
October 10 2018
The broker says the cancer treatment developer could potentially take the entire share of the growth market from ageing cyclotron companies
cholesterol on a dial
September 24 2018
"The formation of ProBiotix Health and appointment of Adam Reynolds as chairman continues a successful strategy of building value in each division which is materialised by forming separate legal entities and taking them to a public listing,” said chief executive Stephen O’Hara

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use